source
- Molecular residual disease testing offers earlier insight into cancer treatment responseIn oncology, determining whether cancer has truly been eliminated after therapy is challenging because imaging and standard clinical criteria often miss low‑level disease. Molecular residual diseas…
- FDA pauses enrollment in Biohaven's epilepsy trials after earlier depression trial failureFDA placed a partial clinical hold on Biohaven's Kv7 potassium channel agonist, BHV-7000 (opakalim), halting enrollment of new patients in two late-stage focal epilepsy studies. The pause follows…